Apheresis Market Size, Share & Industry Analysis By Product (Equipment and Consumables & Accessories), By Technology (Centrifugation-Based Apheresis and Membrane Filtration Apheresis), By Procedure (Plasmapheresis, Plateletpheresis, Leukapheresis, Erythrocytapheresis, and Others), By End-user (Hospitals & Transfusion Centers, Blood Collection Centers & Blood Banks, and Others), and Regional Forecast, 2026-2034

The global apheresis market is experiencing significant growth, primarily driven by the increasing demand for procedures such as plasma exchange, red blood cell exchange, and others for treating conditions such as neurological diseases and autoimmune disorders.

Additionally, procedures such as removing white blood cells before chemotherapy and CAR-T cell therapy are expected to drive the utilization of apheresis devices, supporting the market expansion.

Apheresis Market Driver

Rising Demand for Plasma-Derived Therapies to Fuel Growth

Over the past few years, there has been a growing demand for plasma-derived medicinal products (PDMPs), including immunoglobulins, albumin, and clotting factors. Chronic conditions such as primary immunodeficiency, hemophilia, and autoimmune disorders are rising, which require regular plasma-based treatments. This is driving the demand for large-scale donor plasmapheresis and advanced automated collection systems to improve plasma yield and safety. As a result, there is increasing support from governments for national plasma collection procedures, which is expected to drive market growth.

• For instance, in September 2022, Grifols, S.A. signed an agreement with Canadian Blood Services to help Canada become self-sufficient in immunoglobulins. The enhanced domestic plasma collection and immunoglobulin production capabilities.

Download Free sample to learn more about this report.

According to data published by the World Health Organization (WHO) in August 2025, about 7.74 million people worldwide were living with sickle-cell disease in 2021, with approximately 515,000 new births that year, mainly in Sub-Saharan Africa, which accounts for nearly 80.0% of the global cases.

Apheresis Market Restraint

High Capital and Operational Costs of Apheresis Systems May Hinder Market Growth

Apheresis equipment and disposables involve significant upfront investment and recurring operational costs. Moreover, it includes additional expenses for maintenance, calibration, and sterile consumables. Additionally, in low- and middle-income countries, there are limited reimbursement and affordability issues, leading to limited penetration outside major hospitals or donor centers. Further, the limited availability of trained staff and compliance with international safety standards are increasing overall costs, restricting market expansion.

Apheresis Market Opportunity

Expansion of Cell & Gene Therapy and Immunotherapy Programs to Offer Lucrative Opportunities for Leukapheresis

Recently, there has been a rapid expansion in cell and gene therapies (CGT), such as CAR-T and TCR-T cell therapies. This is expected to represent a major opportunity for leukapheresis technology providers. In such a scenario, apheresis systems are critical for harvesting specific immune cells used in ex vivo cell engineering and reinfusion. Moreover, the surge in CGT clinical trials globally is driving the demand for high-precision, closed-loop leukapheresis systems with GMP compliance. In response, the vendors are integrating digital traceability, cryogenic compatibility, and scalability, which is expected to offer significant opportunities for biopharma collaborations.

• For instance, in October 2024, Intellia Therapeutics, Inc. initiated the global Phase 3 HAELO clinical trial of NTLA-2002 (lonvoguran ziclumeran), an investigational CRISPR-based gene editing therapy for hereditary angioedema (HAE), dosing the first patient in January 2025.

Segmentation

Key Insights

The report covers the following key insights:

• Prevalence/Incidence of Key Diseases, By Key Countries/ Region, 2024
• Advancements in Apheresis Systems
• Key Industry Developments (Mergers, Acquisitions & Partnerships, and Others)

Analysis by Product

Based on product, the market is divided into equipment and consumables & accessories.

The consumables & accessories segment is expected to account for the largest market share during the forecast period. The segment’s growth is mainly due to procedure-linked, repeat usage in every apheresis session, unlike devices, which are one-time capital purchases. Moreover, the key players are continuously upgrading tubing, collection sets, and filters with biocompatible and low-shear materials.

Analysis by Technology

Based on technology, the market is categorized into centrifugation-based apheresis and membrane filtration apheresis.

The centrifugation-based apheresis segment is expected to account for the largest market share during the forecast period. The centrifugation-based apheresis is considered the gold standard for separating multiple blood components with high precision and speed. It supports nearly all applications, including plasma, platelets, leukocytes, and RBCs, making it efficient and versatile, which is expected to drive the segment’s growth.

Analysis by Procedure

The market, on the basis of procedure, is subdivided into plasmapheresis, plateletpheresis, leukapheresis, erythrocytapheresis, and others.

The plasmapheresis segment is expected to hold a major share during the forecast period. The use of plasmapheresis procedures is increasing due to their broad therapeutic applications in autoimmune, neurological, and metabolic disorders. Such a rise in procedures is supported by the growing incidence of neurological diseases, including Guillain-Barré syndrome (GBS) and myasthenia gravis (MG), which are driving the usage of apheresis equipment and consumables, thereby contributing to the segment’s growth.

• For instance, according to data from the Journal of Neuroinflammation in November 2021, GBS has an annual incidence rate of 1-2 cases per 100,000 individuals worldwide.

Analysis by End-user

In terms of end-user, the market is categorized into hospitals & transfusion centers, blood collection centers & blood banks, and others.

The hospitals & transfusion centers segment held the largest market share in 2024. These settings perform both therapeutic and emergency apheresis procedures for the management of complex patients. As a result, integrating apheresis units within the hematology, neurology, and nephrology departments of these settings is vital to enhance procedural throughput. Additionally, the significant number of hospitals worldwide is anticipated to increase the installation of such devices, which is expected to fuel the segment’s growth.

• For instance.

Regional Analysis

Request for Customization   to gain extensive market insights.

On the basis of region, the market has been analyzed across North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa.

North America held the largest global apheresis market share in 2024. The growth is attributed to the large network of plasma donation centers and high volumes of therapeutic procedures, which are driving the rapid adoption of apheresis devices and disposables. Additionally, the significant number of cell & gene therapy manufacturing and clinical trials is also propelling the utilization of leukapheresis and photopheresis in the region.

Asia Pacific is expected to grow at the highest CAGR during the forecast period. The growth is attributed to a large patient pool of hematological disorders, including sickle cell anemia, as well as autoimmune and renal disorders, which drive the demand for procedures such as plasmapheresis, leukapheresis, and erythrocytapheresis. This is encouraging key players to expand their product offerings in the region.

• For instance, according to data published by ScienceDirect in August 2024, the Global Burden of Disease (GBD) study of 2021 estimated that 1.2 million individuals in India were living with sickle cell disease (SCD).

Key Players Covered

The global apheresis market is dominated by major players, including Haemonetics Corporation, Terumo Corporation, Asahi Kasei Medical Co., Ltd., and Nikkiso Co., Ltd. These companies have a significant focus on expanding their product portfolios and global reach to gain a substantial market share.

The report will include the profiles of the following key players:

• Asahi Kasei Medical Co., Ltd. (Japan)
• Terumo Corporation (Japan)
• Haemonetics Corporation (U.S.)
• Fresenius Kabi AG (Germany)
• Braun SE (Germany)
• Kaneka Corporation (Japan)
• Nikkiso Co., Ltd. (Japan)
• Baxter (U.S.)
• SB-KAWASUMI LABORATORIES, INC. (Japan)

Key Industry Developments

• May 2025: San Antonio-based BBG Advanced Therapies, a subsidiary of nonprofit BioBridge Global, launched the world's first mobile leukapheresis center, designed to collect immune cells for cell and gene therapies across more than 63,000 square miles.
• August 2022: Terumo Corporation partnered with Asahi Kasei Medical Co., Ltd. to advance the development of therapeutic apheresis systems and their global expansion. The collaboration enhanced treatment options for immune and neurological disorders through innovative cell and blood therapy technologies.